Ariad looks to boost Iclusig sales with two new deals
This article was originally published in Scrip
Ariad Pharmaceuticals has signed two deals for the commercialization of its leukemia drug Iclusig (ponatinib), which has had disappointing sales since its launch in the US and Europe. Ariad has signed over exclusive rights to market Iclusig in Central and Eastern Europe to Angelini Pharma – an Italian-headquartered firm, and has also entered a deal with Japanese firm Otsuka Pharmaceutical.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.